The select committee met with oral submitters and received written submissions. To each oral submitter, we asked several questions: are they comfortable proceeding without waiting for the Pfizer data, which we were told would be available in a month or so, or in the coming months, quote, unquote, is what Pfizer says. Every oral submitter said to us, "Yes". We then asked: do they believe progressing without the Pfizer data on the basis of the international evidence provides more benefits than waiting for that data? Again, every submitter said yes.